By Suzannah Weiss — 2018
The truth behind those pre-Ayahuasca dietary and drug restrictions.
Read on www.vice.com
CLEAR ALL
As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.
1
People of color are dealing with racism all the time, in large and small ways, and even dealing with racism in healthcare, even dealing with racism in therapy.
Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.
In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.
A new study finds widespread exclusion of minorities in psychedelic research.
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).
Could there be one factor that links together conflict, climate change, racism, anxiety and eating disorders?